# A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

> **NCT07665450** · PHASE3 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 1000 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ramantamig
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07665450
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-09
- **Primary completion:** 2030-09-04
- **Final completion:** 2035-02-02
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665450, "A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07665450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*